A detailed history of Marshall Wace, LLP transactions in Design Therapeutics, Inc. stock. As of the latest transaction made, Marshall Wace, LLP holds 17,192 shares of DSGN stock, worth $107,450. This represents 0.0% of its overall portfolio holdings.

Number of Shares
17,192
Previous 24,280 29.19%
Holding current value
$107,450
Previous $81,000 13.58%
% of portfolio
0.0%
Previous 0.0%

Shares

6 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

SELL
$3.19 - $5.88 $22,610 - $41,677
-7,088 Reduced 29.19%
17,192 $92,000
Q2 2024

Aug 14, 2024

BUY
$3.23 - $4.77 $78,424 - $115,815
24,280 New
24,280 $81,000
Q3 2023

Nov 14, 2023

SELL
$2.05 - $8.14 $107,378 - $426,373
-52,380 Reduced 46.39%
60,542 $142,000
Q2 2023

Aug 14, 2023

SELL
$4.99 - $7.64 $339,305 - $519,497
-67,997 Reduced 37.58%
112,922 $711,000
Q1 2023

May 15, 2023

BUY
$5.5 - $9.77 $374,555 - $665,346
68,101 Added 60.36%
180,919 $1.04 Million
Q4 2022

Feb 14, 2023

BUY
$7.86 - $17.2 $886,749 - $1.94 Million
112,818 New
112,818 $1.16 Million

Others Institutions Holding DSGN

About Design Therapeutics, Inc.


  • Ticker DSGN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 55,807,900
  • Market Cap $349M
  • Description
  • Design Therapeutics, Inc. a preclinical-stage biopharmaceutical company, engages in the development of therapies for the treatment of genetic diseases caused by nucleotide repeat expansions. The company's portfolio of products comprises Friedreich Ataxia, a monogenic, autosomal recessive, progressive multi-system disease that affects organ syste...
More about DSGN
Track This Portfolio

Track Marshall Wace, LLP Portfolio

Follow Marshall Wace, LLP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Marshall Wace, LLP, based on Form 13F filings with the SEC.

News

Stay updated on Marshall Wace, LLP with notifications on news.